3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
4
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Melanoma
14
Uterine Cervical Neoplasms
2
Prostatic Neoplasms
2
Neoplasm Metastasis
2
Hematologic Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Xeroderma Pigmentosum
1
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uveal Melanoma
1
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Solid Tumor
1
Sarcoma
1
Neuroblastoma
1
Multiple Myeloma
1
Lymphoma
1
Lymphatic Metastasis
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hemangiosarcoma
1
Esophageal Neoplasms
1
Colorectal Neoplasms, Hereditary Nonpolyposis
1
Colorectal Cancer Metastatic
1
Colonic Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Merkel Cell
1
Carcinoma
1
Interventions
Gemcitabine
3
Nivolumab
2
temoporfin
1
spartalizumab
1
polysaccharide-K
1
pembrolizumab
1
nimotuzumab
1
devimistat
1
dalotuzumab
1
bemarituzumab
1
belinostat
1
Transurethral Resection of Prostate
1
Radiotherapy, Intensity-Modulated
1
Radiotherapy
1
Radiofrequency Ablation
1
Oxaliplatin
1
Morphine
1
Methadone
1
Leucovorin
1
Ipilimumab
1
Interviews as Topic
1
Injections
1
Immunotherapy
1
Heavy Ion Radiotherapy
1
Fluorouracil
1
Erlotinib Hydrochloride
1
Docetaxel
1
Cryosurgery
1
Cisplatin
1
Brachytherapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Adenocarcinoma
×
Ipilimumab
×
Clear all
NCT04315155
2020-10-28
BENEFIT
University of Utah
Phase 1
Withdrawn